Frontline inotuzumab ozogamicin in older adults with Philadelphia chromosome-negative B-ALL: an exploratory pooled analysis of efficacy and safety
Abstract
Older adults (aged ≥ 55 years) with Philadelphia chromosome-neg-ative B-cell acute lymphoblastic leukemia (B-ALL) frequently present with adverse cytogenetic features, poor treatment tolerance, and inferior long-term outcomes [1, 2]. While intensive chemotherapy remains the standard first-line approach, its clinical efficacy in this cohort is limited. This poor prognosis is further compounded by a higher incidence of adverse genetic abnormalities, such as TP53 mutations, which confer resistance to conventional chemotherapy [3, 4]. In addition to genetic factors, immune dysregulation and inflammatory signatures are critical drivers of chemotherapy resistance in older adults. For instance, overexpression of the inflammatory biomarker TREM1 has been shown to promote an immunosuppressive microenvironment and predict intrinsic chemotherapy resistance and poor survival in acute myeloid leukemia [5]. Furthermore, exploring novel molecular pathways like ferroptosis and profiling specific circulatory growth factors have emerged as critical strategies for predicting chemotherapy responsiveness and improving clinical outcomes in